NZ611463A - Inactivated dengue virus vaccine with aluminium-free adjuvant - Google Patents

Inactivated dengue virus vaccine with aluminium-free adjuvant

Info

Publication number
NZ611463A
NZ611463A NZ611463A NZ61146310A NZ611463A NZ 611463 A NZ611463 A NZ 611463A NZ 611463 A NZ611463 A NZ 611463A NZ 61146310 A NZ61146310 A NZ 61146310A NZ 611463 A NZ611463 A NZ 611463A
Authority
NZ
New Zealand
Prior art keywords
dengue virus
aluminium
virus vaccine
inactivated dengue
free adjuvant
Prior art date
Application number
NZ611463A
Inventor
Isabelle Solange Lucie Knott
Dirk Gheysen
Jean-Francois Toussaint
Benoit Baras
Jean-Paul Prieels
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Priority to NZ700477A priority Critical patent/NZ700477A/en
Publication of NZ611463A publication Critical patent/NZ611463A/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed is an immunogenic composition comprising at least one inactivated dengue virus antigen and an aluminium-free adjuvant, wherein the adjuvant comprises a combination of 3-Deacylated monophosphoryl lipid A (3D–MPL) and QS21. Also disclosed is a method for making the said composition and its use for preventing, ameliorating or treating disease caused by dengue virus in a subject.
NZ611463A 2009-02-17 2010-02-16 Inactivated dengue virus vaccine with aluminium-free adjuvant NZ611463A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ700477A NZ700477A (en) 2009-02-17 2010-02-16 Inactivated dengue virus vaccine with aluminium-free adjuvant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15306009P 2009-02-17 2009-02-17
NZ59462410 2010-02-16

Publications (1)

Publication Number Publication Date
NZ611463A true NZ611463A (en) 2014-10-31

Family

ID=51796553

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ611463A NZ611463A (en) 2009-02-17 2010-02-16 Inactivated dengue virus vaccine with aluminium-free adjuvant

Country Status (1)

Country Link
NZ (1) NZ611463A (en)

Similar Documents

Publication Publication Date Title
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
CY1121211T1 (en) HERPITAS VIRUS VACCINE
CR10101A (en) NEW COMPOSITION
BRPI0813307B8 (en) immunogenic composition, vaccine, and process for making the vaccine
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
GB201101665D0 (en) Immunogenic compositions
TW200722101A (en) Novel composition
CA2763359C (en) New human rotavirus strains and vaccines
AR092896A1 (en) IMMUNOGENIC COMPOSITIONS
MX2009006178A (en) Salmonella vaccine.
BR112015005056A2 (en) combination vaccines with meningococcus serogroup b and d / t / p
BR112013025424A2 (en) processes for producing an immunogenic composition, and for manufacturing a vaccine, and immunogenic composition
AR108829A1 (en) VACCINE AGAINST INFECTIOUS BRONCHITIS VIRUS
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
NZ591950A (en) Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
BR112015022582A2 (en) nucleic acid molecule, plasmid, vaccine, and use of a plasmid
NZ630133A (en) Vaccines for serogroup x meningococcus
MX2023012530A (en) Adjuvanted vaccine composition and methods.
MX2013003245A (en) Bvdv vaccine.
BR112013017939A2 (en) thermostable lyophilized immunogenic composition, method of preparing a composition comprising an attenuated viral antigen and vesicles and uses of the composition or formulation
NZ591188A (en) West nile virus vaccine
WO2011074006A3 (en) Vaccine composition
NZ614147A (en) Equine rhinitis vaccine
MX2009011312A (en) Vaccination regimen for b-cell vaccines.
NZ611463A (en) Inactivated dengue virus vaccine with aluminium-free adjuvant

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 FEB 2017 BY AJ PARK

Effective date: 20150424

LAPS Patent lapsed